| 영문 | cardiovascular system | 한글 | 심장혈관계 |
|---|---|---|---|
| 설명 | 신체의 혈액순환을 담당하는 기관. 즉 심장과 혈관을 통칭해서 이르는 말이다. |
||
| 영문 | autonomic nervous system | 한글 | 자율신경계 |
|---|---|---|---|
| 설명 | 사람의 의지와 관계없이, 침을 흘리거나 소화운동 등과 같은 스스로 조정이 되어 움직이는 신경계이며 여기에는 다음과 같은 두 가지가 있다. 1.교감신경계(sympathetic nervous system)-사람이 위험상태에 이르렀을 경우에 흥분이 되는 자율신경계. 즉 심박수의 증가, 소화기 운동의 감소 등의 일이 이곳을 통해서 일어난다. 교감신경이 흥분되면 교감신경의 말단에서 epinephrine, norepinephrine 등의 물질이 분비되고 이것들에 의해서 말초장기가 변화를 일으킨다. 하지만 장기에 따라서 epinephrine이나 norepinephrine의 수용체를 가지고 있어서 여러 가지 다른 장기의 반응을 볼 수가 있다. 수용체는 다음과 같다. -알파수용체(alpha-receptor): 말초혈관의 수축, 기관지의 수축, 동공의 근육의 수축 -베타1수용체(beta 1-receptor): 심장에 존재하는 수용체, 심장을 빨리 뛰게하는 역할을 한다. -베타2수용체(beta 2-receptor): 혈관의 이완, 기관지의 이완, 즉 각 장기들은 그 장기가 가지고 있는 교감신경의 수용체에 따라 교감신경의 흥분(교감신경 말단에서의 epinephrine의 분비)에 대한 반응이 달라진다(예-교감신경이 흥분시에 beta 1-수용체를 가지고 있는 심장은 빨리 뛰게 된다. 교감신경 흥분시에 동공의 근육이 수축해서 동공의 크기가 커진다) 2.부교감신경계(parasympathetic nervous system)-교감신경과 반대로 작용한다. 즉 사람이 졸리거나 쉴 경우에 흥분한다. 부교감신경이 흥분할 때에는 신경의 말단에서 아세칠콜린의 분비가 일어나고 이것으로 인해서 각 장기의 변화가 일어난다. |
||
| 영문 | TNM staging system | 한글 | 종양병기분류계통 |
|---|---|---|---|
| 설명 | 종양의 병기(stage)를 결정하는 한 방법. T는 Tumor(종양)를 뜻하며 원발병터의 크기, 주위조직으로의 침윤정도 등에 따라 T1, T2, T3, T4(숫자가 높을 수록 주위로 침윤이 많다) 등으로 나눈다. N은 Node(림프절)를 뜻하며 침범된 림프절의 갯수, 크기, 위치 등에 따라 N1, N2, N3 등으로 나눈다. M은 Metastasis(전이)를 뜻하며 원격전이의 유무에 따라 M0, M1 등으로 나눈다. 이상의 방법으로 T, N, M이 결정되면 이들을 조합하여 최종적인 병기를 결정한다. 이렇게 결정된 병기는 치료 방침 결정과 예후 판단에 매우 중요하다. |
||
| 영문 | central nervous system(CNS) | 한글 | 중추신경계 |
|---|---|---|---|
| 설명 | 신경계는 중추신경계와 말초신경계로 분류할 수가 있다. 중추신경계란 뇌와 척수로 구성되어 있는 신경계를 이르는 말이다. 말초신경계란 이 이외의 모든 신경계를 이르는 말이다. |
||
| CSD | carotid sinus denervation; cat scratch disease; combined system disease; conditionally streptomycin ... |
|---|---|
| FCS | faciocutaneoskeletal syndrome; fecal containment system; feedback control system; fetal calf serum; ... |
| HCPCS | Health Care Financing Administration common procedural collecting system; Health Care Financing Admi... |
| HIS | health information system; Health Interview Survey; histatin; histidine; hospital information system... |
| HMIS | hazardous materials identification system; hospital medical information system |
| NADH-cytochrome P-450 reductase | <enzyme> A component of the cytochrome p-450sca monoxygenase system Registry number: EC 1.6.2.- (26 Jun 1999) |
|---|---|
| NADPH-cytochrome c2 reductase | <enzyme> An enzyme catalyzing the reduction of 2 ferricytochrome c2 to 2 ferrocytochrome c2 at the expense of NADPH. Synonym: cytochrome c2 reductase. (05 Mar 2000) |
| succinate cytochrome c oxidoreductase | <enzyme> A portion of the electron transport chain, catalyzing the transfer of electrons from succinate to cytochrome c via fad, ubiquinone, and cytochrome b. The first step is catalyzed by succinate dehydrogenase (ec 1.3.99.1), the other steps are not well characterised. Registry number: EC 1.- (12 Dec 1998) |
| QH2 cytochrome C reductase | <enzyme> Membrane bound complex in the mitochondrial inner membrane, responsible for electron transfer from reduced coenzyme Q to cytochrome C. Contains cytochromes b and c1 and iron sulphur proteins. (18 Nov 1997) |
| triazole cytochrome P-450-obtusifoliol-14-demethylase | <enzyme> Key enzyme in plant sterol biosynthesis Registry number: EC 1.- Synonym: tcpo demethylase, obtusifoliol 14 alpha-methyl demethylase (26 Jun 1999) |
| ubiquinol-cytochrome-c reductase | <enzyme> An 11-subunit enzyme complex that acts as an electron transferring protein in the mitochondrial respiratory chain. The enzyme complex catalyses the oxidation of ubiquinol to ubiquinone and ferrocytochrome c in the presence of ferricytochrome c. It contains cytochromes b-562, b-566, and c1 as well as an iron ferredoxin. Chemical name: Ubiquinol-ferricytochrome-c oxidoreductase Registry number: EC 1.10.2.2 (12 Dec 1998) |
| acetyl-activating enzyme | A ligase that catalyses the reaction of acetate and CoA and ATP to form AMP, pyrophosphate, and acetyl-CoA. A key step in the activation of acetate. Synonym: acetate thiokinase, acetate-CoA ligase, acetyl-activating enzyme, acetyl-CoA synthetase. (05 Mar 2000) |
| acyl-activating enzyme | <enzyme> Fatty acid thiokinase (long-chain), a ligase forming acyl-CoA, AMP, and pyrophosphate from long-chain fatty acids, ATP, and coenzyme A. Activity is independent of phosphatidylcholine Registry number: EC 6.2.1.3 Synonym: acyl-activating enzyme, dodecanoyl-CoA synthetase, fatty acid thiokinase (long chain), acid-coenzyme a ligase, fatty acid-CoA ligase, acyl-CoA synthetase, acyl-CoA ligase, coash ligase, ciprofibroyl-CoA synthetase, pristanoyl-CoA synthetase, palmityl CoA synthetase, palmitoyl CoA synthetase, palmitoyl CoA ligase, fatty acyl-CoA synthetase, very long chain fatty acid acyl-CoA synthetase, vlcfa acyl-CoA synthetase, nafenopin-CoA ligase, palmitoyl-CoA synthase, faa2 gene product, faa2p protein, vlacs enzyme (26 Jun 1999) |
| adaptive enzyme | Inducible enzyme, an enzyme that can be detected in a growing culture of a microorganism, after the addition of a particular substance (inducer) to the culture medium, but was not detectable prior to the addition and can act on the inducer. A prototype is the beta-galactosidase of Escherichia coli, synthesised upon the addition of various galactosides, whether or not these are good substrates. Compare: constitutive enzyme. Synonym: adaptive enzyme. (05 Mar 2000) |
| allosteric enzyme | <biochemistry, chemistry> A regulatory enzyme whose activity is modified by the noncovalent binding of a particular metabolite at a site (the allosteric site) other than the active site. (09 Oct 1997) |
| amino acid activating enzyme | <enzyme> Enzymes catalyzing the formation of a specific aminoacyl-tRNA from an amino acid and adenosine 5'-triphosphate with the concomitant formation of adenosine 5'-monophosphate and pyrophosphate. Synonym: amino acid activating enzyme, aminoacyl-tRNA ligases. (05 Mar 2000) |
| angiotensin-converting enzyme | <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I. Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). Drugs that inhibit ACE are used to treat hypertension and congestive heart failure. See: angiotensin-converting enzyme inhibitor Acronym: ACE (12 Aug 2000) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| angiotensin-converting enzyme secretase | <enzyme> Converts ace from a membrane-bound to a soluble form; not inhibited by thiol, serine or acid enzyme inhibitor but is inhibited by edta and 1,10-phenanthroline Registry number: EC 3.4.99.- Synonym: ace secretase (26 Jun 1999) |
| Antibody Directed Enzyme Prodrug Therapy | <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately. The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects. Acronym: ADEPT (14 Nov 1997) |